ERCC2 and agammaglobulinemia: The present results indicate that patients with confirmed ERCC2 deficiency or the diagnosis of TTD1 should be investigated for antibody deficiency to enable early initiation of antibody replacement therapy, which could protect ERCC2 deficient patients from acquiring severe and potentially life-threatening infections.